regarded as a disease of increased pulmonary arterial vasoconstriction, it is now clear that vascular remodeling in PAH is far more complex. Fibrosis, apoptosis resistance, proliferation, and a tendency toward glycolytic cellular metabolism are key endophenotypes observed in pulmonary artery endothelial cells, pulmonary artery smooth muscle cells (PASMCs), pericytes, and adventitial fibroblasts of patients with PAH (1) . Even in monogenic subtypes (e.g., BMPR2 mutation), interplay between these mechanisms contributes to the wider PAH histopathophenotype, particularly plexogenic and hypertrophic vascular lesions. Realization that PAH is due ultimately to multiple overlapping molecular pathways has led to a strategic shift in the therapeutic approach clinically. Indeed, several lines of evidence suggest that targeting multiple different signaling pathways simultaneously is optimal for improving outcome in patients with PAH (2).
Despite these advances, PAH remains a morbid disease with a significant impact on longevity, quality of life, and health care expenditure (3).
Arguably, there has been no major progress in the treatment of PAH for 13 years. The 14 PAH-specific drugs approved by the U.S. Food and Drug Admin- 
